Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-03 · accession 0001562180-25-001997 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-03-04 | 2025-03-03 | AKBA | Burke Steven Keith | SVP, Chief Medical Off | S - Sale | $1.83 | -7,144 | 809.1K | -0.9% | -$13.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-03 | S | D | 7,144 | $1.83 | 809,090 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. (F2) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. |